Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H
Department of Neurosurgery, Kagawa National Children's Hospital, Kagawa, Japan.
Appl Radiat Isot. 2011 Dec;69(12):1823-5. doi: 10.1016/j.apradiso.2011.05.029. Epub 2011 Jun 12.
The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT). We have treated 23 glioblastoma patients with BNCT without any additional chemotherapy since 1998. The median survival time (MST) of BNCT was 19.5 months, and 2-year, 3-year and 5-year survival rates were 26.1%, 17.4% and 5.8%, respectively. This clinical result of BNCT in patients with GBM is superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment.
本研究的目的是评估基于硼苯丙氨酸（BSH）的术中硼中子俘获治疗（IO-BNCT）以及基于BSH和双对氨基苯甲醚（BPA）的非术中硼中子俘获治疗（NO-BNCT）的临床疗效。自1998年以来，我们已对23例胶质母细胞瘤患者进行了硼中子俘获治疗，未进行任何额外的化疗。硼中子俘获治疗的中位生存时间（MST）为19.5个月，2年、3年和5年生存率分别为26.1%、17.4%和5.8%。与传统治疗的历史数据相比，硼中子俘获治疗在胶质母细胞瘤患者中的这一临床结果优于单纯的传统放疗治疗。
